研究業績

2014年度・英文業績

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy.

Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T, Yoshino R, Kenmotsu H, Saitoh J, Harada H, Naito T, Murakami H, Tomizawa Y, Matsuura M, Saito R, Nakajima T, Yamada M, Takahashi T.
SpringerPlus 4:152.

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.

Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Yamamoto N, Takahashi T.
Annals of thoracic medicine 10(1):61-6.

Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.

Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, Imai H, Taira T, Murakami H, Endo M, Takahashi T.
Cancer chemotherapy and pharmacology 75(3):521-526.

Primary malignant melanoma of the trachea: A case report.

Imai H, Kiyohara Y, Yoshikawa S, Kusutani N, Ono A, Taira T, Kenmotsu H, Harada H, Naito T, Murakami H, Sano T, Fuji H, Endo M, Nakajima T, Takahashi T.
Oncology letters 9(2):657-660.

Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer.

Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, Hisamatsu Y, Tokito T, Imai H, Akamatsu H, Ono A, Kaira K, Murakami H, Endo M, Mori K, Takahashi T, Yamamoto N.
Supportive care in cancer 23(6):1699-1708.

Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.

Okamura I, Imai H, Mori K, Ogura K, Isoda A, Mihara K, Matsumoto M, Saito R, Takahashi T, Ikeda T.
International journal of hematology 101(1):46-51.

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

Ko R, Kenmotsu H, Hisamatsu Y, Akamatsu H, Omori S, Nakashima K, Oyakawa T, Wakuda K, Shukuya T, Ono A, Imai H, Taira T, Naito T, Murakami H, Mori K, Endo M, Ohde Y, Takahashi K, Takahashi T.
International journal of clinical oncology 2014 Oct 25. [Epub ahead of print]

Identification of actionable mutations in malignant pleural mesothelioma.

Shukuya T, Serizawa M, Watanabe M, Akamatsu H, Abe M, Imai H, Tokito T, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Ohde Y, Nakajima T, Yamamoto N, Koh Y.
Lung cancer (Amsterdam, Netherlands) 86(1):35-40.

Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.

Yoshino R, Imai H, Mori K, Takei K, Tomizawa M, Kaira K, Yoshii A, Tomizawa Y, Saito R, Yamada M.
Molecular and clinical oncology 2(5):731-736.

Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells.

Kotake M, Sato K, Mogi C, Tobo M, Aoki H, Ishizuka T, Sunaga N, Imai H, Kaira K, Hisada T, Yamada M, Okajima F.
Cellular signalling 26(11):2326-32.

Ionotropic and metabotropic proton-sensing receptors involved in airway inflammation in allergic asthma.

Aoki H, Mogi C, Okajima F.
Mediators Inflamm. 2014(2014):712962.

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.

Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Takahashi T.
Medical oncology (Northwood, London, England) 31(8):88.

Multiplexed molecular profiling of lung cancer using pleural effusion.

Akamatsu H, Koh Y, Kenmotsu H, Naito T, Serizawa M, Kimura M, Mori K, Imai H, Ono A, Shukuya T, Taira T, Murakami H, Ohde Y, Endo M, Nakajima T, Takahashi T, Yamamoto N.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9(7):1048-52.

Perianal metastasis of non-small cell lung cancer.

Imai H, Inafuku K, Wakuda K, Ono A, Taira T, Kenmotsu H, Watanabe R, Naito T, Murakami H, Ito I, Endo M, Tanabe H, Nakajima T, Takahashi T.
Internal medicine 53(11):1149-52.

Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.

Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
Respiratory investigation 52(2):101-6.

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T, Yamamoto N.
BMC cancer 14:18.

Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Yamamoto N.
Neoplasma 61(2):233-40.

Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.

Ono A, Kenmotsu H, Watanabe M, Serizawa M, Mori K, Imai H, Taira T, Naito T, Murakami H, Nakajima T, Ohde Y, Endo M, Yamamoto N, Koh Y, Takahashi T.
Annals of oncology 25(10):1948-53.

Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer.

Hisamatsu Y, Murakami H, Akamatsu H, Kimura M, Mori K, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Naito T, Endo M, Nakajima T, Takahashi T, Yamamoto N.
Thoracic Cancer 5(2):121–125.

Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma.

Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M.
Inflamm Res. 63(9):789-96.

Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk.

Y Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, Nagashima T, Ohtaki Y, Kaira K, Sunaga N, Yanagitani N, Yoshino R, Tsunekawa K, Igai H, Kamiyoshihara M, Usui K, Lezhava A, Tomizawa Y, Ishikawa T, Murakami M, Hayashizaki Y, Takeyoshi I.
Biomed Rep. 2(5):719-724.

Clinicopathological significance of ASC-amino acid transporter 2 (ASCT2) expression in pancreatic ductal carcinoma.

Kaira K, Sunose Y, Arakawa K, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Takeyoshi I.
Histopathology. 66(2):234-43.

Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report.

Kaira K, Okamura T, Takahashi H, Horiguchi N, Sunaga N, Hisada T, Yamada M.
J Med Case Rep. 8:119.

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M, Oyama T, Takeyoshi I.
Br J Cancer. 110(8):2030-9.

The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.

Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N.
Am J Clin Oncol. 37(2):144-7.

The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.

Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N.
Am J Clin Oncol. 37(2):144-7.

Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status.

Ohtaki Y, Shimizu K, Kakegawa S, Nagashima T, Nakano T, Atsumi J, Enokida Y, Igai H, Ibe T, Sugano M, Kamiyoshihara M, Kawashima O, Kaira K, Sunaga N, Takeyoshi I.
Mol Clin Oncol. 2014;2:187-96.

The effects of concomitant GERD, dyspepsia, and rhinosinusitis on asthma symptoms and FeNO in asthmatic patients taking controller medications.

Ishizuka T, Hisada T, Kamide Y, Aoki H, Seki K, Honjo C, Sakai H, Kadowaki M, Umeda Y, Morikawa M, Anzai M, Ameshima S, Ishizaki T, Dobashi K, Yamada M, Kusano M.
J Asthma Allergy. 2014 Sep 5;7:131-9.

Prognostic significance of Amino Acid Transporter Expression (LAT1, ASCT2 and xCT) in Surgically Resected Tongue Cancer.

Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, Takayasu Y, Takahashi K, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, Chikamatsu K.
Br J Cancer. 2014;110:2506-13.

Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.

Suzuki S, Kaira K, Ohshima Y, Ishioka NS, Sohda M, Yokobori T, Miyazaki T, Oriuchi N, Tominaga H, Kanai Y, Tsukamoto N, Asao T, Tsushima Y, Higuchi T, Oyama T, Kuwano H.
Br J Cancer. 2014;110:1985-91.

Detection of human papillomavirus (HPV) in patients with squamous cell carcinoma and the clinical characteristics of HPV-positive cases.

Shimizu A, Kato M, Takeuchi Y, Sano T, Kaira K, Uezato H, Ishikawa O.
Br J Dermatol. 2014;171:779-85.

2014年度・和文業績

電顕像でダイニン外腕の欠損を認めたKartagener syndromeの1例

久田剛志, 萩原治夫, 設楽直也, 石塚全
THE LUNG-perspectives, 22 (3): 229, 2014

【職業性アレルギー疾患診療ガイドライン発刊について】 気管支喘息 分類・疫学・診断

久田剛志
アレルギー・免疫, 21 (5): 762-767, 2014

喀痰好酸球増多を契機に好酸球性細気管支炎を疑った1例

三浦陽介, 富澤由雄, 桑子智人, 富澤麻衣, 高橋源, 吉井明弘, 斎藤龍生, 山田正信
アレルギー, 63 (9): 1265-1270, 2014

2013年度・英文業績
Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.

Kaira K, Endo M, Shukuya T, Kenmotsu H, Naito T, Ono A, Tsuya A, Nakamua Y, Takahashi T, Murakami H, Kondo H, Nakajima T, Yamamoto N.
Ann Nucl Med. 2013 May;27(4):314-24.

Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.

Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N.
Clin Lung Cancer. 2013 Jul;14(4):440-5.

Perfusion evaluation of lung cancer: assessment using dual-input perfusion computed tomography.

Nakano S, Gibo J, Fukushima Y, Kaira K, Sunaga N, Taketomi-Takahashi A, Tsushima Y, Mori M.
J Thorac Imaging. 2013 Jul;28(4):253-62.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.
Oncogene. 2013 Aug 22;32(34):4034-42.

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor–tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N.
Anticancer Res. 2013 Aug;33(8):3279-84.

Oxidative stress potentially enhances FcεRI-mediated leukotriene C4 release dependent on the late-phase increase of intracellular glutathione in mast cells.

Seki K, Hisada T, Kawata T, Kamide Y, Dobashi K, Yamada M, Mori M, Okajima F, Ishizuka T.
Biochem Biophys Res Commun. 2013 Sep 27;439(3):357-62.

Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.

Kaira K, Sunose Y, Ohshima Y, Ishioka NS, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Yamaguchi A, Segawa A, Ide M, Mori M, Oyama T, Takeyoshi I.
BMC Cancer. 2013 Oct 16;13:482.

Prognosis of patients with brain metastasis from non-small cell lung cancer according to gefitinib administration.

Ayabe E, Kaira K, Harada H, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Nishimura T, Yamamoto N, Takahashi T.
J Tumor 2013 Oct;18 1(5):20-23.

Clinicopathological significance of L-type amino acid transporter 1 (LAT1) expression in patients with adenoid cystic carcinoma.

Kaira K, Toyoda M, Shino M, Sakakura K, Takahashi K, Tominaga H, Oriuchi N, Kanai Y, Oyama T, Chikamatsu K.
Pathol Oncol Res. 2013 Oct;19(4):649-56.

Biological correlation of ¹⁸F-FDG uptake on PET in pulmonary neuroendocrine tumors.

Kaira K, Murakami H, Endo M, Ohde Y, Naito T, Kondo H, Nakajima T, Yamamoto N, Takahashi T.
Anticancer Res. 2013 Oct;33(10):4219-28.

Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.

Nobusawa A, Kim M, Kaira K, Miyashita G, Negishi A, Oriuchi N, Higuchi T, Tsushima Y, Kanai Y, Yokoo S, Oyama T.
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1692-700.

Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.

Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N.
Lung Cancer. 2013 Oct;82(1):103-8.

Proton-sensing ovarian cancer G protein-coupled receptor 1 on dendritic cells is required for airway responses in a murine asthma model.

Aoki H, Mogi C, Hisada T, Nakakura T, Kamide Y, Ichimonji I, Tomura H, Tobo M, Sato K, Tsurumaki H, Dobashi K, Mori T, Harada A, Yamada M, Mori M, Ishizuka T, Okajima F.
PLoS One. 2013 Nov 11;8(11):e79985.

FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer.

Noriaki Sunaga, Kyoichi Kaira, Takeshi Hisada and Masanobu Yamada.
World J Respirol 3(3):104-109.

Long-term survival of more than 3 years among patients with advanced non-small cell lung cancer treated with chemotherapy.

Kaira R, Kaira K, Shukuya T, Kenmotsu H, Ono A, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N, Takahashi T.
World J Respirology 2013 Nov;28 3(3):110-115.

Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N.
Lung Cancer. 2013 Dec;82(3):449-54.

¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.

Kaira K, Yamamoto N, Endo M, Kenmotsu H, Naito T, Ono A, Murakami H, Ohde Y, Nakajima T, Takahashi T.
Oncol Rep. 2014 Jan;31(1):209-15.

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma.

Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kasahara N, Kawashima O, Hisada T, Saito R, Yamada M.
Br J Cancer. 2014;110:2047-53.

Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.

Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T, Yamamoto N.
Lung Cancer. 2014 Feb;83(2):197-204.

Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status.

Ohtaki Y, Shimizu K, Kakegawa S, Nagashima T, Nakano T, Atsumi J, Enokida Y, Igai H, Ibe T, Sugano M, Kamiyoshihara M, Kawashima O, Kaira K, Sunaga N, Takeyoshi I.
Mol Clin Oncol. 2014 Mar;2(2):187-196.

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Shimizu K, Kaira K, Tomizawa Y, Sunaga N, Kawashima O, Oriuchi N, Tominaga H, Nagamori S, Kanai Y, Yamada M, Oyama T, Takeyoshi I.
Br J Cancer. 2014 Mar 6.[Epub ahead of print]

Prognostic impact of (18)F-FDG uptake on PET in non-small cell lung cancer patients withpostoperative recurrence following platinum-based chemotherapy.

Kaira K, Yamamoto N, Kenmotsu H, Murakami H, Ono A, Naito T, Endo M, Takahashi T.
Respir Investig. 2014 Mar;52(2):121-8.

CD98 as a promising biomarker of prognosis in biliary tract cancer.

Kaira K, Sunose Y, Oriuchi N, Kanai Y, Takeyoshi I.
Hepatobiliary Pancreat Dis Int. 2014 13:654-7.

Clinical Features of Patients with Invasive Thymoma: A retrospective analysis of 61 Cases.

Imai H, Kaira K, Yoshino R, Sato K, Shimizu K, Kawashima O, Tanaka S, Mori M.
Surgical Practice 2014 in press.

Small cell lung cancer with VGCC antibody-positive paraneoplastic limbic encephalitis: a case report.

Kaira K, Okamura T, Takahashi H, Horiguchi N, Sunaga N, Hisada T, Yamada M.
J Med Case Rep 2014 in press.

Solitary pituitary metastasis resulting from pulmonary large cell neuroendocrine carcinoma.

Watanabe T, Kaira K, Mizuide M, Sunaga N, Shibusawa N, Hisada H, Satoh T, Mori M, Yamada M.
World J Respirology 2014 in press.

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.

Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, Kondo H, Nakajima T, Yamamoto N.
Int J Clin Oncol. 2013;18:371-9.

Perfusion Evaluation of Lung Cancer: Assessment Using Dual-input Perfusion Computed Tomography.

Nakano S, Gibo J, Fukushima Y, Kaira K, Sunaga N, Taketomi-Takahashi A, Tsushima Y, Mori M.
J Thorac Imaging. 2013;28:253-62.

2013年度・和文業績

成人喘息患者における喘息症状および鼻・副鼻腔炎症状のコントロールを把握するためのGスケール問診票の開発

石塚 全, 久田 剛志, 上出 庸介, 青木 悠, 関 香織, 草野 元康
Progress in Medicine33(7): 1643-1648,2013

緊張性気胸で突然死した間質性肺炎合併皮膚筋炎の1例

岸 史子, 神山 由佳, 永井 弥生, 橋爪 真之, 鶴巻 寛朗, 久田 剛志, 石川 治
皮膚科の臨床55(5):641-644,2013

がん地域連携におけるPersonal Cloud Serverを用いた診療ネットワーク

浅尾 高行, 解良 恭一, 郡 隆之
日本遠隔医療学会雑誌9(2):224-225,2013

2012年度・英文業績

¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?

Kaira K, Endo M, Shukuya T, Kenmotsu H, Naito T, Ono A, Tsuya A, Nakamua Y, Takahashi T, Murakami H, Kondo H, Nakajima T, Yamamoto N.
Neoplasma. 2012;59(3):257-63.

Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.

Kaira K, Yamamoto N.
Onkologie. 2012;35(1-2):8-9.

Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.

Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N.
Eur J Cancer. 2012 May;48(8):1244-54.

Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.

Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M.
Int J Cancer. 2012 Apr 15;130(8):1733-44.

MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer.

Kaira K, Okumura T, Nakagawa K, Ohde Y, Takahashi T, Murakami H, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N.
Pathol Oncol Res. 2012 Apr;18(2):439-47

Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer.

Kaira K, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Endo M, Kondo H, Nakajima T, Yamamoto N.
Int J Surg Pathol. 2012 Jun;20(3):223-32.

Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer.

Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T, Takeyoshi I.
Br J Cancer. 2012 Aug 7;107(4):632-8.

Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.

Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N.
Med Oncol. 2012 Sep;29(3):1663-72

Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: gene expression associated with metastatic potential in human lung cancer.

Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Kakegawa S, Sugano M, Ibe T, Nagashima T, Kaira K, Sunaga N, Ohtaki Y, Atsumi J, Takeyoshi I.
Oncol Rep. 2012 Nov;28(5):1727-35.

Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro.

Sato Y, Ebara T, Sunaga N, Takahashi T, Nakano T.
Anticancer Res. 2012 Nov;32(11):4877-81.

Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.

Nakajima Y, Takagi H, Kakizaki S, Horiguchi N, Sato K, Sunaga N, Mori M.
Anticancer Res. 2012 Dec;32(12):5251-62.

2012年度・和文業績

[Case report: a case of IgG4-associated autoimmune pancreatitis accompanying liver inflammatory pseudotumor].

Iizuka T, Shibusawa N, Yoshida S, Mizuide M, Ono A, Yamazaki Y, Takahashi H, Satoh T, Kusano M, Mori M.
Nihon Naika Gakkai Zasshi. 2012 Feb 10;101(2):468-71. Japanese.

2011年度・英文業績

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.
Mol Cancer Ther. 2011 Feb;10(2):336-46.

Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.

Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N.
Lung Cancer. 2011 Feb;71(2):144-50.

Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.

Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Naito T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N.
J Thorac Oncol. 2011 Mar;6(3):606-13.

Thenar muscle metastasis as recurrence of pulmonary squamous cell carcinoma.

Kaira K, Ayabe E, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Takahashi M, Yamamoto N.
Asia Pac J Clin Oncol. 2011 Mar;7(1):15-6.

18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors.

Kaira K, Murakami H, Miura S, Kaira R, Akamatsu H, Kimura M, Ono A, Tsuya A, Nakamura Y, Naito T, Takahashi T, Endo M, Yamamoto N.
Ann Nucl Med. 2011 May;25(4):247-53.

Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors.

Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N.
J Nucl Med. 2011 May;52(5):705-11.

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.

Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T, Yamamoto N.
Virchows Arch. 2011 May;458(5):615-20.

A systemic review of PET and biology in lung cancer.

Kaira K, Oriuchi N, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N.
Am J Transl Res. 2011 Aug 15;3(4):383-91.

Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.

Kaira K, Okumura T, Ohde Y, Takahashi T, Murakami H, Kondo H, Nakajima T, Yamamoto N.
Anticancer Res. 2011 Sep;31(9):2763-71.

Prevalence of asthma symptoms based on the European Community Respiratory Health Survey questionnaire and FENO in university students: gender differences in symptoms and FENO.

Ishizuka T, Matsuzaki S, Aoki H, Yatomi M, Kamide Y, Hisada T, Tsuburai T, Dobashi K, Ohshima K, Akiyama K, Mori M.
Allergy Asthma Clin Immunol. 2011 Sep 19;7(1):15.

Genetic organization and mode of action of a novel bacteriocin, bacteriocin 51: determinant of VanA-type vancomycin-resistant Enterococcus faecium.

Antimicrob Agents Chemother. 2011 Sep;55(9):4352-60. doi: 10.1128/AAC.01274-10. Epub 2011 Jun 27.
Yamashita H, Tomita H, Inoue T, Ike Y.

Intracellular glutathione redox status in human dendritic cells regulates IL-27 production and T-cell polarization.

Kamide Y, Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, Koga Y, Uno K, Hamuro J, Mori M.
Allergy. 2011 Sep;66(9):1183-92.

Extracellular acidification induces connective tissue growth factor production through proton-sensing receptor OGR1 in human airway smooth muscle cells.

Matsuzaki S, Ishizuka T, Yamada H, Kamide Y, Hisada T, Ichimonji I, Aoki H, Yatomi M, Komachi M, Tsurumaki H, Ono A, Koga Y, Dobashi K, Mogi C, Sato K, Tomura H, Mori M, Okajima F.
Biochem Biophys Res Commun. 2011 Oct 7;413(4):499-503.

Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors.

Kaira K, Ohde Y, Endo M, Nakagawa K, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Kondo H, Nakajima T, Yamamoto N.
Oncol Rep. 2011 Oct;26(4):931-7.

Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence.

Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Oriuchi N, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N. Anticancer Res. 2011 Nov;31(11):3775-82.

The role of [¹⁸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors.

Kaira K, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N. Cancer Imaging. 2011 Nov 30;11:195-201. doi: 10.1102/1470-7330.2011.0028. Review.

L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma.

Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N.
Anticancer Res. 2011 Dec;31(12):4075-82.

Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.

Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N.
Lung Cancer. 2011 Dec;74(3):419-25.

2011年度・和文業績

[Case report: a young adult case of poorly differentiated lung adenocarcinoma showing the resistance mutation T790M of EGFR before treatment with tyrosine kinase inhibitors].

Okamura T, Shibusawa N, Koga Y, Horiguchi N, Ogashiwa T, Satoh K, Hisada T, Satoh T, Ishizuka M, Mori M.
Nihon Naika Gakkai Zasshi. 2011 Jul 10;100(7):1959-62. Japanese.

植物性気管支異物の1例

鶴巻寛朗*1, 久田剛志*1, 新井秀雄*3, 小山徹也*2, 石塚全*1, 森昌朋*1
群馬大学医学部附属病院呼吸器・アレルギー内科(第1内科)*1, 群馬大学大学院病理診断学/病理部*2, 群馬大学医学部附属病院病理部*3 THE LUNG perspectives 19(4): 445-445, 2011.

2010年度・英文業績

Long-term survivors of more than 5 years in advanced non-small cell lung cancer.

Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N.
Lung Cancer. 2010 Jan;67(1):120-3.

Analysis on the co-localization of asbestos bodies and Fas or CD163 expression in asbestos lung tissue by in-air micro-pixe.

Matsuzaki S, Shimizu Y, Dobashi K, Nagamine T, Satoh T, Ohkubo T, Yokoyama A, Ishii Y, Kamiya T, Arakawa K, Makino S, Utsugi M, Ishizuka T, Tanaka S, Shimizu K, Mori M.
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):1-11.

Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer.

Imai H, Sunaga N, Shimizu Y, Kakegawa S, Shimizu K, Sano T, Ishizuka T, Oyama T, Saito R, Minna JD, Mori M.
Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):153-64.

Eosinophilic bronchiolitis indicating eosinophilic airway disease with overexpression of carcinoembryonic antigen in sinus and bronchiole: case report.

Yanagitani N, Shimizu Y, Kazama T, Dobashi K, Ishizuka T, Mori M.
J Biol Regul Homeost Agents. 2010 Jan-Mar;24(1):99-102.

Decreased interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with discrepancy of CXCL12/CXCR4 axis.

Shimizu Y, Dobashi K, Endou K, Ono A, Yanagitani N, Utsugi M, Sano T, Ishizuka T, Shimizu K, Tanaka S, Mori M.
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):449-61.

Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.

Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N.
J Thorac Oncol. 2010 Apr;5(4):460-5.

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.

Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, Ono A, Igawa S, Shukuya T, Murakami H, Tsuya A, Nakamura Y, Endo M, Yamamoto N.
Lung Cancer. 2010 Apr;68(1):99-104.

Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.

Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Iwasaki Y, Shimizu K, Iijima H, Tsurumaki H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M.
Lung Cancer. 2010 May;68(2):253-7.

Mechanism of gastroesophageal reflux in patients with obstructive sleep apnea syndrome.

Kuribayashi S, Kusano M, Kawamura O, Shimoyama Y, Maeda M, Hisada T, Ishizuka T, Dobashi K, Mori M.
Neurogastroenterol Motil. 2010 Jun;22(6):611-e172.

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M.
Lung Cancer. 2010 Jul;69(1):99-104.

Promotion of cell spreading and migration by vascular endothelial-protein tyrosine phosphatase (VE-PTP) in cooperation with integrins.

Mori M, Murata Y, Kotani T, Kusakari S, Ohnishi H, Saito Y, Okazawa H, Ishizuka T, Mori M, Matozaki T.
J Cell Physiol. 2010 Jul;224(1):195-204.

Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.

Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N.
J Clin Oncol. 2010 Aug 10;28(23):3746-53.

Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer.

Iwasaki Y, Sunaga N, Tomizawa Y, Imai H, Iijima H, Yanagitani N, Horiguchi K, Yamada M, Mori M.
Ann Surg Oncol. 2010 Aug;17(8):2222-8.

JNK1 and JNK2 differently regulate IL-12 production in THP-1 macrophage cells.

Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, Koga Y, Shimizu Y, Kawata T, Matsuzaki S, Aoki H, Kamide Y, Mori M.
Cytokine. 2010 Aug;51(2):127-31

Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M.
Exp Ther Med. 2010 Sep;1(5):799-808.

Prognostic and predictive factors in resected non-small-cell lung cancer.

Kaira K, Yamamoto N.
Expert Opin Med Diagn. 2010 Sep;4(5):373-81.

Protective effect of resolvin E1 on the development of asthmatic airway inflammation.

Aoki H, Hisada T, Ishizuka T, Utsugi M, Ono A, Koga Y, Sunaga N, Nakakura T, Okajima F, Dobashi K, Mori M.
Biochem Biophys Res Commun. 2010 Sep 10;400(1):128-33.

Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells.

Matsuzaki S, Ishizuka T, Hisada T, Aoki H, Komachi M, Ichimonji I, Utsugi M, Ono A, Koga Y, Dobashi K, Kurose H, Tomura H, Mori M, Okajima F.
J Immunol. 2010 Oct 15;185(8):4863-72

CD98 expression is associated with the grade of malignancy in thymic epithelial tumors.

Kaira K, Takahashi T, Abe M, Akamatsu H, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Kondo H, Nakajima T, Endo M, Yamamoto N.
Oncol Rep. 2010 Oct;24(4):861-7.

Extracellular acidification stimulates IL-6 production and Ca(2+) mobilization through proton-sensing OGR1 receptors in human airway smooth muscle cells.

Ichimonji I, Tomura H, Mogi C, Sato K, Aoki H, Hisada T, Dobashi K, Ishizuka T, Mori M, Okajima F.
Am J Physiol Lung Cell Mol Physiol. 2010 Oct;299(4):L567-77.

Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer.

Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K.
Nucl Med Biol. 2010 Nov;37(8):911-6.

Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.

Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Mori M, Endo K.
AJR Am J Roentgenol. 2010 Nov;195(5):1204-11.

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.

Kaira K, Endo M, Asakura K, Tsuya A, Nakamura Y, Naito T, Murakami H, Takahashi T, Yamamoto N.
Ann Nucl Med. 2010 Dec;24(10):697-705.

Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.

Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M, Kanai Y.
Anticancer Res. 2010 Dec;30(12):4819-28.

2010年度・和文業績

S-1単剤投与にて腫瘍の縮小を1年以上続けた進行非小細胞肺癌の1例

鶴巻寛朗*1, 富澤由雄*1, 土屋卓磨*1, 鈴木淳*1, 飯島浩宣*1, 吉井明弘*1, 渡辺覚*1, 佐藤浩二*1, 上出庸介*1, 森昌朋*2, 斎藤龍生*1
*1独立行政法人国立病院機構西群馬病院・呼吸器科, *2群馬大学大学院病態制御内科呼吸器・アレルギー内科
癌と化学療法 37(11): 2147-2149, 2010.

2009年度・英文業績

Clinicopathological features of patients with bronchial-associated lymphoid tissue lymphoma.

Imai H, Sunaga N, Kaira K, Kawashima O, Yanagitani N, Sato K, Tomizawa Y, Hisada T, Ishizuka T, Hirato J, Saito R, Nakajima T, Mori M.
Intern Med. 2009;48(5):301-6.

Glutathione redox regulates TGF-beta-induced fibrogenic effects through Smad3 activation.

Ono A, Utsugi M, Masubuchi K, Ishizuka T, Kawata T, Shimizu Y, Hisada T, Hamuro J, Mori M, Dobashi K.
FEBS Lett. 2009 Jan 22;583(2):357-62.

Forearm muscle metastasis as an initial clinical manifestation of lung cancer.

Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Tsuchiya T, Hisada T, Mori M.
South Med J. 2009 Jan;102(1):79-81.

CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma.

Shimizu Y, Dobashi K, Imai H, Sunaga N, Ono A, Sano T, Hikino T, Shimizu K, Tanaka S, Ishizuka T, Utsugi M, Mori M.
Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):43-51.

Pulmonary traumatic pneumatocele and hematoma.

Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M.
Jpn J Radiol. 2009 Feb;27(2):100-2.

Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study.

Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M.
Int J Cancer. 2009 Mar 1;124(5):1152-60.

Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Shimizu Y, Sunaga N, Dobashi K, Fueki M, Fueki N, Makino S, Mori M.
BMC Infect Dis. 2009 Apr 22;9:47.

Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.

Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M.
Cancer Sci. 2009 Apr;100(4):753-8.

PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role.

Utsugi M, Dobashi K, Ono A, Ishizuka T, Matsuzaki S, Hisada T, Shimizu Y, Kawata T, Aoki H, Kamide Y, Mori M.
J Immunol. 2009 May 1;182(9):5225-31.

Resolvin E1 as a novel agent for the treatment of asthma.

Hisada T, Ishizuka T, Aoki H, Mori M.
Expert Opin Ther Targets. 2009 May;13(5):513-22.

Multiple lung metastases presenting as ground-glass opacities in a pulmonary adenocarcinoma: a case report.

Yanagitani N, Kaira K, Ishizuka T, Aoki H, Utsugi M, Shimizu Y, Sunaga N, Endou K, Hisada T, Mori M.
Cases J. 2009 May 29;2:6910.

L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M.
J Surg Oncol. 2009 Jun 1;99(7):433-8.

L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.

Imai H, Kaira K, Oriuchi N, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M.
Histopathology. 2009 Jun;54(7):804-13

Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Kaira K, Sunaga N, Yanagitani N, Kawata T, Utsugi M, Shimizu K, Ebara T, Kawamura H, Nonaka T, Ishikawa H, Sakurai H, Suga T, Hara K, Hisada T, Ishizuka T, Nakano T, Mori M.
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):109-14.

Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T, Mori M.
Lung Cancer. 2009 Oct;66(1):120-6.

18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.

Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K.
J Nucl Med. 2009 Nov;50(11):1770-6.

CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.

Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M.
Ann Surg Oncol. 2009 Dec;16(12):3473-81.

2009年度・和文業績

慢性閉塞性肺疾患の急性増悪に対するgarenoxacinの臨床効果

久田剛志1, 石塚全1, 青木悠1, 柳谷典子1, 小野昭浩1, 今井久雄1, 砂長則明1, 宇津木光克1, 古賀康彦1, 岩崎靖樹1, 吉野麗子1, 土橋邦生2, 桑原英眞3, 森昌朋1
1群馬大学大学院医学系研究科病態制御内科学呼吸器・アレルギー内科, 2群馬大学医学部保健学科, 3独立行政法人国立病院機構沼田病院
新薬と臨牀 58(10): 1808-1820, 2009.

[A case of cryptogenic organizing pneumonia with eosinophilic infiltration which was difficult to distinguish from nonspecific interstitial pneumonia].

Yanagitani N, Ishizuka T, Hironaka M, Kaira K, Imai H, Kawata T, Utsugi M, Shimizu Y, Sunaga N, Hisada T, Mori M.
Nihon Kokyuki Gakkai Zasshi. 2009 Apr;47(4):286-90. Japanese

GemcitabineとS-1の併用療法にて多発骨転移が著明に改善した高齢者肺癌の1例

解良恭一*1, 柳谷典子*1, 砂長則明*1, 今井久雄*1, 宇津木光克*1, 川田忠嘉*1, 久田剛志*1, 清水公裕*2, 石塚全*1, 森昌朋*1
*1群馬大学大学院医学系研究科・病態制御内科学, *2群馬大学大学院医学系研究科・臓器病態外科学
癌と化学療法 36(2): 299-300, 2009.

孤立結節影を呈する非結核性抗酸菌症と肺癌を合併した1例

解良恭一1),2), 仲川奈緒子3), 谷野功典3), 棟方充3)
1)群馬大学大学院医学系研究科病態制御内科学呼吸器アレルギー内科(1), 2)静岡県立静岡がんセンター呼吸器内科, 3)福島県立医科大学呼吸器内科
日本呼吸器学会雑誌 47(10): 969-970, 2009.

サルコイドーシスの病勢評価におけるFDG-PETの有用性

解良恭一1),2), 服部健史3), 今野哲3), 西村正治3)
1)群馬大学大学院医学系研究科病態制御内科学呼吸器アレルギー内科(1), 2)静岡県立静岡がんセンター呼吸器内科, 3)北海道大学医学部第1内科
日本呼吸器学会雑誌 47(12): 1166-1167, 2009.;

2008年度・英文業績

Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.

Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, Ishizuka T, Endo K, Mori M.
Lung Cancer. 2008 Feb;59(2):203-10.

A Novel Regulatory Mechanism of Myosin Light Chain Phosphorylation via Binding of 14-3-3 to Myosin Phosphatase.

Koga Y, Ikebe M. Mol Biol Cell. 2008 Mar;19(3):1062-71.

2008年度・和文業績

[A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].

Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Shimizu Y, Kawata T, Hisada T, Shimizu K, Tsuchiya T, Ishizuka T, Mori M.
Gan To Kagaku Ryoho. 2008 Sep;35(9):1587-9. Japanese.